期刊文献+

抗磷脂综合征患者血栓事件的危险因素分析 被引量:8

Analysis of risk factors in development of thrombosis in patients with antiphospholipid syndrome
下载PDF
导出
摘要 目的:探讨影响抗磷脂综合征(antiphospholipid syndrome,APS)患者血栓事件发生的危险因素。方法:回顾性分析北京大学人民医院收治的61例APS患者血栓事件的发生特点,评价血栓事件与患者临床及免疫学指标的相关性,包括性别、年龄、有无血小板减少、吸烟、高血压、糖尿病、高脂血症和抗磷脂抗体等。结果:70.49%APS患者发生血栓事件,其中动脉血栓发生率36.67%,静脉血栓发生率39.34%,下肢静脉血栓和脑梗塞最常见,分别占37.7%和24.59%,其次为肺栓塞、血栓性微血管病、肾梗死和脾梗死。抗心磷脂抗体阳性和高血压分别是静脉和动脉血栓事件的独立危险因素。结论:抗心磷脂抗体阳性者易发生静脉血栓,而合并高血压的APS患者易发生动脉血栓。 Objective:To analyze the risk factors in the development of thrombosis in antiphospholipid syndrome(APS) patients.Methods: We retrospectively analyzed the characteristics of thrombosis in 61 APS patients.Clinical and laboratory parameters such as sex,age,thrombocytopenia,smoking,hypertension,diabetes mellitus,hyperlipidemia and anti-phospholipid antibodies were investigated to find out the risk factors of thrombosis.Results: Thrombosis was found in 70.49% APS patients,of whom,the prevalence of arterial and venous thrombosis were 36.67% and 39.34%,respectively.Deep vein thrombosis of lower extremity(37.7%) and cerebral infarction(24.59%) were the most common thrombosis events,and then pulmonary embolism,thrombotic microangiopathy and renal artery thrombosis were also common in APS patients.The positive anti-cardiolipin antibody and hypertension were the independent risk factors for venous and arterial thrombosis,respectively.Conclusion: Anti-cardiolipin antibody is associated with a higher risk of venous thrombosis,and hypertension is associated with arterial thrombosis.
出处 《北京大学学报(医学版)》 CAS CSCD 北大核心 2012年第5期788-791,共4页 Journal of Peking University:Health Sciences
关键词 抗磷脂综合征 血栓形成 危险因素 Antiphospholipid syndrome Thrombosis Risk factors
  • 相关文献

参考文献14

  • 1Sangle NA, Smock KJ. Antiphospholipid antibody syndrome [ J ]. Arch Pathol Lab Med, 2011, 135(9) : 1092 -1096.
  • 2Lackner K J, Peetz D, yon Landenberg P. Revision of the Sapporo criteria for the antiphospholipid syndrome: coming to grips with evidence and Thomas Bayes? [ J]. Thromb Haemost, 2006, 95(6) : 917 -919.
  • 3Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease ex- pression in a cohort of 1,000 patients [ J ]. Arthritis Rheum, 2002, 46(4) : 1019 -1027.
  • 4Drijkoningen J, Damoiseaux J, van Paassen P, et al. Clinical manifestations of the anti-phospholipid syndrome as defined by the updated Sapporo classification criteria [ J ]. Ann Rheum Dis, 2007, 66(10) : 1407 - 1408.
  • 5吴庆军,朱燕林,唐福林.抗磷脂综合征100例临床特征分析[J].中华风湿病学杂志,2007,11(11):675-678. 被引量:18
  • 6Turiel M, Sarzi-Puttini P, Peretti R, et al. Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study [J]. Stroke, 2005, 36(7): 1490-1494.
  • 7Neville C, Ranch J, Kassis J, et al. Thromboembolic risk in pa- tients with high titre anticardiolipin and multiple antiphospholipid antibodies [ J ]. Thromb Haemost, 2003, 90 ( 1 ) : 108 - 115.
  • 8Ruffatti A, Del Ross T, Ciprian M, et at. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multi- centre, retrospective follow-up study[ J]. Ann Rheum Dis, 2009, 68 (3) : 397 - 399.
  • 9de Souza AW, Silva NP, de Carvalho JF, et al, Impact of hyper- tension and hyperhomocysteinemia on arterial thrombosis in prima- ry antiphospholipid syndrome [J]. Lupus, 2007, 16(10) : 782 - 787.
  • 10Danowski A, de Azevedo MN, de Souza Papi JA, et al. Determi- nants of risk for venous and arterial thrombosis in primary antiphos- pholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus [ J ]. J Rheumatol, 2009, 36 (6) : 1195 - 1199.

二级参考文献7

  • 1吴庆军,唐福林.抗磷脂综合征//蒋明,张奉春.风湿病诊断与诊断分析.上海:上海科学技术出版社,2004:127-142.
  • 2Wilson WA, Gharavi AE, Koike T, at al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum, 1999, 42:1309-1311.
  • 3Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1982, 25: 1271-1277.
  • 4Cervara R, Piette JC, Font J, et al. Antiphospholipid syndrome, clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum, 2002, 46: 1019-1027.
  • 5Munoz-Rodriguez FJ, Front J, Cervera R, et al. Clinical study and follow-up of 100 patients with the antiphospholipid syn- drome. Semin Arthritis Rheum, 1999, 29: 182-190.
  • 6Vianna JL, Khamashta MA, Ordi-Ros J, et al. Comparison of the primary and secondary antiphospholipid syndrome: an European multicenter study of 114 patients. Am J Med, 1994, 96: 3-9.
  • 7Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb I laemost, 2006, 4: 295-306.

共引文献17

同被引文献80

引证文献8

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部